Test Price
2,800 AED✅ Home Collection Available
KCNQ4 Gene Sequencing (Autosomal Dominant Deafness Type 2A, DFNA2A) Test in UAE
Executive Summary & Core Metrics
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Certified Laboratory Processing.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available daily from 8 AM to 11 PM).
- Clinical Guidance: Telephonic Post-Test Clinical Interpretation by a DHA-Licensed Consultant Medical Genetics.
- Insurance: Direct Billing Verification via WhatsApp: +971 54 548 8731
Test Overview & Methodology
This NGS‑based genetic test analyzes the KCNQ4 gene to detect pathogenic variants causing autosomal dominant nonsyndromic sensorineural hearing loss type 2A (DFNA2A). The test provides definitive molecular diagnosis, enabling accurate genetic counseling and personalized audiological management. Next‑generation sequencing covers all coding exons and flanking intronic regions, with Sanger confirmation for all clinically significant findings.
| Feature | Our Test (DNA Labs UAE) | Standard Sequencing (Limited) |
|---|---|---|
| Methodology | NGS with Sanger confirmation | Sanger sequencing of selected exons |
| Turnaround | 3–4 Weeks | 2–3 Weeks |
| Detection Rate | >99.9% for point mutations & indels | ~90% (limited to known hotspots) |
| Price (AED) | 2,800 | 1,800 – 2,200 |
Physician Insight & Safety Protocols
“As a Consultant Medical Genetics, I emphasize that KCNQ4 gene sequencing provides critical diagnostic confirmation for DFNA2A. However, genetic results must always be interpreted in the context of the patient’s audiometric profile and family pedigree. This test does not replace comprehensive audiological evaluation. Patients should discuss the implications with their genetic counselor or ENT specialist before making any management decisions.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA License 9294403
Advisory & Precautions
This genetic test is specifically indicated for individuals with a suspected hereditary hearing loss pattern consistent with DFNA2A. It is not a substitute for routine hearing screening or evaluation of acquired hearing loss. Always disclose any history of ototoxic medication exposure or head trauma, as these may influence interpretation. Do not delay clinical follow-up based solely on preliminary genetic findings.
Safety Exclusion & Emergency Red Flags
- Exclusion Criteria: This gene test is not indicated for non‑genetic hearing loss (e.g., acoustic trauma, chronic otitis media, presbycusis).
- Emergency Red Flags: Acute vestibular crisis, sudden profound hearing loss, facial weakness, or new‑onset severe headache — proceed to the nearest emergency department immediately.
Patient FAQ & Clinical Guidance
1. What is the KCNQ4 gene test used for?
The KCNQ4 gene test is used to confirm a diagnosis of autosomal dominant sensorineural hearing loss type 2A (DFNA2A). It identifies pathogenic variants in the KCNQ4 gene and helps guide genetic counseling, family screening, and long-term audiological management.
2. Can I do the test at home in Dubai or Abu Dhabi?
Yes, our VIP Mobile Phlebotomy service covers all UAE regions — including Dubai, Abu Dhabi, Sharjah, and the Northern Emirates — with ISO‑certified cold‑chain logistics ensuring sample integrity from collection to laboratory. Collections are available daily from 8 AM to 11 PM.
3. Will my insurance cover the KCNQ4 genetic test?
We provide instant direct insurance billing verification. Contact our dedicated team via WhatsApp at +971 54 548 8731 to confirm coverage with your provider under UAE DHA genetic testing regulations.
UAE Regulatory & Data Privacy Adherence
This diagnostic service operates in full compliance with:
- Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) – ensuring genetic data confidentiality and processing safeguards.
- Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields – governing electronic health records and telemedicine.
- Federal Decree-Law No. 4 of 2016 on Medical Liability – establishing clinical safety standards and patient consent requirements.
DNA Labs UAE (DHA License 1143) maintains ISO 9001:2015 certification (Cert: INT/EGQ/2509DA/3139) and follows ACMG standards for variant interpretation.
Clinical & Logistical Metadata
| Test Name | KCNQ4 Gene Sequencing (Autosomal Dominant Deafness Type 2A, DFNA2A) |
| Price (AED) | 2,800 |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Peripheral Whole Blood (EDTA) – VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection |
| Methodology Used | Next-Generation Sequencing (NGS) with Sanger Confirmation |
| ICD-10-CM Code | H90.3 (Sensorineural hearing loss, bilateral) |
| LOINC Code | 81327-2 (KCNQ4 gene targeted mutation analysis in blood) |
| DHA Facility License & Laboratory Address | License No. 1143 — Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians